the impact of 24hr infusions on clinical practice

21
The impact of 24hr infusions on clinical practice Tim Hills Nottingham University Hospitals NHS Trust

Upload: others

Post on 03-Jun-2022

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: The impact of 24hr infusions on clinical practice

The impact of 24hr infusions on clinical practice

Tim HillsNottingham University Hospitals NHS Trust

Page 2: The impact of 24hr infusions on clinical practice

Outline• Why use CIV beta-lactam antibiotics?• Drug-stability work stream• Initial experience of CIV beta-lactams• Clinical Outcomes of there use in OPAT• Future plans

Page 3: The impact of 24hr infusions on clinical practice

PK/PD consideration

Page 4: The impact of 24hr infusions on clinical practice

• Meropenem 1.5g load then 1g tdsvs 500mg load then 3g/24hr CIV (3 x 8h infusions)

• Higher plasma and subcut. levels (black) with CIV.

Roberts et al JAC 2009

Page 5: The impact of 24hr infusions on clinical practice

(Doses expressed as piperacillin content) Roberts et al critical care med 2009

• Piperacillin bolus 4g 6hrly vs 12-16g/24hr CIV

• Higher likelihood of PK/PD target attainment with CIV dosing in critically ill with normal renal function. (bolus target =60% T>MIC, CIV = 100% T>MIC)

Page 6: The impact of 24hr infusions on clinical practice

þFlucloxacillinýMeropenem

Page 7: The impact of 24hr infusions on clinical practice

National Advice• Advice for clinicians, pharmacy and

nursing staff on considerations for OPAT services– Drug stability, including design of studies– Use of buffers– Compounding– Procurement– Storage– Administration

Mark Santillo, Abi Jenkins and Conor Jamiesonhttps://www.sps.nhs.uk/wp-content/uploads/2018/07/OPAT-v1-April-18.pdf

Page 8: The impact of 24hr infusions on clinical practice

Citrate Buffer

3Ca2+

Ca2+- O-

O-

O-Ca2+

Ca2+

6Na+

Page 9: The impact of 24hr infusions on clinical practice

Citrate Buffer – potential issues

Page 10: The impact of 24hr infusions on clinical practice

Monitored blood results

• N = 11• No patient required CIV interruption

• Low Ca2+: 1 x deranged LFTs, 1 x Low Vitamin D

Page 11: The impact of 24hr infusions on clinical practice

Study 2:Clinical Outcomes• Design: Retrospective obervational study• Inclusion: Patient episodes treated with buffered CIV beta-lactams

on OPAT from July 2017-October 2018.• Outcomes: based on BSAC NORS Infection Outcomes

– Cured: Completed OPAT duration with resolution of infection and no long-term antibiotics

– Improved: Completed OPAT with partial resolution of infection but need for further follow-up OR required escalation of antimicrobial therapy.

– Failure: Progression or non-response of infection despite OPAT, required admissions, surgical intervention or died for any reason.

Page 12: The impact of 24hr infusions on clinical practice

CIV Flucloxacillin (8g or 12g/24hours) Primary Infective Diagnosis

Discitis without metalwork (MW)

Discitis with MW

Epidural abscess

Infected total knee replacement

Infective Endocarditis

Malignant otitis externa

Post op wound infection

Psoas abscess

Septicaemia

Spinal infection assoc with MW

Wound infection post op

Osteomyelitis surgically related

N= 18

Page 13: The impact of 24hr infusions on clinical practice

Benzylpenicillin• Single patient-episode of vascular surgery infection

treated with benzylpenicillin 9.6g/24hr (2 x 4.8g concurrent via a dual lumen PICC).

Page 14: The impact of 24hr infusions on clinical practice

Pip/taz 13.5g/24 hour CIV Primary Infective Diagnosis

0

2

4

6

8

10

12

14

16

Bronchiectasis DF NO OM DFOM Empyema Lung abscess Vascular graftinfection

Page 15: The impact of 24hr infusions on clinical practice

Outcomes

0

2

4

6

8

10

12

14

16

18

BenPen 4.8g/24h Fluclox 12g/24h Fluclox 8g/24h PipTaz 13.5g/24h

Cured

Fail

Improved

Hills and Snape Poster #2141

Page 16: The impact of 24hr infusions on clinical practice

Comparison with Historic CohortPiperacillin/tazobactamdose and indication Number Male % Mean age

Proportion “improved” or

“cured”13.5g/24 hours CIV Bronchiectasis 15 53.3% 74.2 years 86.7%*

4.5g three times a day Bronchiectasis 53 41.5% 69.5 years 83.3%*

13.5g/24 hours CIV Diabetic foot osteomyelitis

11 63.6% 62.9 years 81.8%**

4.5g three times a day Diabetic foot osteomyelitis

28 63.0% 61.0 years 60%**

*p=0.73 **p=0.21(Chi squared test) .

Page 17: The impact of 24hr infusions on clinical practice

Clinical outcomes: Study 3• 35 Patient episodes piperacillin/tazobactam

elastomeric CIV treating PsA infections Jan 2015-Dec 2017 on OPAT.

• Resp 42.9%, SSTI 34.6%, Urinary 25.7%, OA 2.9%

J Ferreiro et al Poster #2140

Page 18: The impact of 24hr infusions on clinical practice

J Ferreiro et al Poster #2140

Page 19: The impact of 24hr infusions on clinical practice

Where are we now and for the future?

• Bringing aseptic dispensing of CIVs in-house.– Pilot 7 week study annualised saved us 170 bed days, £5k

• Review of need for additional bloods as limited effects seen (with current citrate loads).– ?Focus on higher risk patient– ?Continue with adjusted calcium monitoring?

• Drug stability work on Piperacillin/Tazobactam and Ceftazidime

Page 20: The impact of 24hr infusions on clinical practice

Summary• CIV beta lactams are a rational, efficacious option

which support OPAT patient care and service delivery.• Stability data is required to support their use

particularly in body-worn devices

Page 21: The impact of 24hr infusions on clinical practice

• Any Questions?